Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview

被引：59

作者：

Andreopoulou E. ^{[1
]}

Sparano J.A. ^{[1
]}

机构：

[1] Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, 1825 Eastchester Road

来源：

Current Breast Cancer Reports | 2013年 / 5卷 / 1期

关键词：

Anthracycline; Chemotherapy; Cytotoxic agents; Drug resistance; MBC; Metastatic breast cancer; Pretreated; Systemic cytotoxic therapy; Taxane;

D O I：

10.1007/s12609-012-0097-1

中图分类号：

学科分类号：

摘要：

Anthracyclines and taxanes are cytotoxic agents commonly used for treatment of breast cancer, including in adjuvant, neoadjuvant, and metastatic settings. Each drug class is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agent have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps for patients with rapidly progressive disease and/or high tumor burden. © 2013 Springer Science+Business Media New York.

引用

页码：42 / 50

页数：8

共 56 条

[1]

Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., Wolff A.C., Sledge Jr. G.W., Wood W.C., Davidson N.E., Weekly paclitaxel in the adjuvant treatment of breast cancer, New England Journal of Medicine, 358, 16, pp. 1663-1671, (2008)

[2]

Carrick S., Parker S., Thornton C.E., Ghersi D., Simes J., Wilcken N., Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev., (2009)

[3]

Sparano J.A., Makhson A.N., Semiglazov V.F., Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, pp. 4522-4529, (2009)

[4]

Chan S., Friedrichs K., Noel D., Pinter T., Van Belle S., Vorobiof D., Duarte R., Gil M.G., Bodrogi I., Murray E., Yelle L., Von Minckwitz G., Korec S., Simmonds P., Buzzi F., Gonzalez Mancha R., Richardson G., Walpole E., Ronzoni M., Murawsky M., Alakl M., Riva A., Crown J., Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, Journal of Clinical Oncology, 17, 8, pp. 2341-2354, (1999)

[5]

Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., Wood W.C., Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193), Journal of Clinical Oncology, 21, 4, pp. 588-592, (2003)

[6]

Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2, New England Journal of Medicine, 344, 11, pp. 783-792, (2001)

[7]

Kardinal C.G., Perry M.C., Weinberg V., Wood W., Ginsberg S., Raju R.N., Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study, Breast Cancer Res Treat, 3, pp. 365-371, (1983)

[8]

Siegel R., Desantis C., Virgo K., Et al., Cancer treatment and survivorship statistics, 2012, CA Cancer J Clin, 62, pp. 220-241, (2012)

[9]

Cardoso F., Di Leo A., Lohrisch C., Bernard C., Ferreira F., Piccart M.J., Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?, Annals of Oncology, 13, 2, pp. 197-207, (2002)

[10]

O'Shaughnessy J., Extending survival with chemotherapy in metastatic breast cancer, Oncologist, 10, SUPPL.. 3, pp. 20-29, (2005)

← 1 2 3 4 5 6 →